FDA chief calls for probe of talks between agency and Biogen before Alzheimer's drug was approved
CBSN
Janet Woodcock, the acting commissioner of U.S. Food and Drug Administration, said on Friday she is calling for an investigation into links between FDA staff and pharmaceutical company Biogen prior to the agency's approval of a controversial Alzheimer's drug.
"Given the ongoing interest and questions, today I requested that [the Office of Inspector General at the U.S. Department of Health & Human Services] conduct an independent review and assessment of interactions between representatives of Biogen and FDA during the process that led to the approval of Aduhelm," Woodcock wrote on Twitter. Aduhelm, the brand name of the Biogen drug, was approved a month ago by the FDA, making it the first new drug for Alzheimer's disease in nearly 20 years cleared for commercial use by government health officials.
Measles is still making headlines in 2025, prompting questions about the life-threatening disease and how to prevent it.
It is common among older adults to not consistently get a full night's rest. But there are ways to improve sleep issues.
Microsoft is pulling the plug on Skype, the pioneering Internet telecommunications and video call platform it bought nearly 14 years ago for $8.5 billion.
Measles cases popping up across the United States, including an outbreak in Texas that has led to the death of a child, are prompting questions about where exactly the illness has been detected.